Nebulized Liposomal Amphotericin B as an Alternative Therapy for an Aspergillus Tracheal Plaque

Invasive pulmonary aspergillosis (IPA) typically affects immunocompromised individuals; however, increasing cases in patients without traditional risk factors suggest evolving host susceptibility and predisposing airway pathology. We present a case of an Aspergillus tracheal plaque in a 68‐year‐old immunocompetent woman with atypical presentation. Due to adverse effects associated with systemic antifungal therapy, treatment was transitioned to nebulized liposomal amphotericin B (LAmB), resulting in complete plaque resolution without complications. This case highlights the potential role of nebulized LAmB as an alternative treatment for tracheal aspergillosis. Further studies are warranted to refine dosing and expand its clinical applications.